Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 4,112 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Stroke
Interventions: Functional Electric Stimulation (FES), Behavioral Assessments, Magnetic Resonance Imaging, EEG, RecoveriX, Delay, BCI-FES; Device · Behavioral · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza Prevention
Interventions: INFLUENZA G1 mHA, Placebo, Al(OH)3; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Miami Lakes, Florida • Lenexa, Kansas • Metairie, Louisiana + 1 more

Conditions: Exercise, Physical Activity, Healthy Adult, Interoception, Affect and Exertion During and Post-exercise
Interventions: Eyes-Closed Interoceptive Aerobic Exercise, Matched Eyes-Open Treadmill Exercise; Behavioral
Lead sponsor: Old Dominion University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Healthy
Interventions: Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: COVID-19
Interventions: AZD7442, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 88
States / cities: Tucson, Arizona • Chula Vista, California • Fresno, California + 59 more

Conditions: Diarrhea Infectious
Interventions: VENBETA6890, Placebo; Drug
Lead sponsor: Mark Klempner; Other
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography, Magnetic Resonance Imaging, Bone Scan, Electronic Health Record Review; Procedure · Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Ramucirumab, Pembrolizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hemophilia A
Interventions: SB-525 (PF-07055480); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 22
States / cities: Little Rock, Arkansas • Duarte, California • Sacramento, California + 7 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Abemaciclib, Nivolumab, Tumor biopsy, Peripheral blood, EORTC QLQ-30; Drug · Procedure · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Coronavirus, COVID-19, Convalescent Plasma
Interventions: Convalescent Plasma; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 16 Years and older
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Solid Tumor Cancers
Interventions: MM-121 (SAR256212), SAR245408; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Boston, Massachusetts • Brookline, Massachusetts • Nashville, Tennessee

Conditions: Pain After TJA
Interventions: Melatonin 5 mg, Placebo Oral Tablet, Magnesium 500Mg Oral Tablet; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Psychological Stress
Interventions: Essential Oil Inhalation, Placebo Aroma Stick; Other
Lead sponsor: dōTERRA International; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pleasant Grove, Utah

Conditions: Healthy Adult Participants
Interventions: [ 18F]GATT-44; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Exercise-specific self-efficacy, Gentle chair exercise, upper body strength training; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 45 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Amyotrophic Lateral Sclerosis
Interventions: VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone; Genetic · Drug
Lead sponsor: Vector Y Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 3 more

Conditions: Cerebral Palsy Children, Motor Disabilities, Developmental Disability, Rehabilitation, Early Intervention, Assistive Technology
Interventions: Therapist Training on Powered Mobility Implementation, Powered Mobility Intervention for Child-Caregiver Dyads; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 12 Months and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Hillsboro, Oregon • Portland, Oregon

Conditions: Depression
Interventions: Esketamine, Cognitive Behavioral Therapy (CBT), Antidepressant; Drug · Behavioral
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland + 1 more

Conditions: Vestibular Schwannoma
Interventions: AAVAnc80-antiVEGF via Akouos Delivery Device; Combination Product
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Baltimore, Maryland • Rochester, Minnesota • Nashville, Tennessee + 1 more

Conditions: Prostate-specific Membrane Antigen Positive Tumors, Prostate Cancer, Breast Cancer, Lung Cancer
Interventions: [Ga-68]PSMA PET/MR; Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Infertility, Endometriosis
Interventions: PRP Experimental; Biological
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 23 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Sensorineural Hearing Loss, Bilateral
Interventions: AAVAnc80-hOTOF via Akouos Delivery Device, AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism; Combination Product
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 6
States / cities: San Francisco, California • Iowa City, Iowa • Boston, Massachusetts + 3 more

Conditions: Healthy Young, Healthy Aging, Stroke
Interventions: Experimental: Treadmill training, Experimental: Overground training, Experimental: Surefooted training; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device

A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults

Eyes-Closed Interoceptive Aerobic Exercise Compared With Matched Eyes-Open Treadmill Exercise in Healthy Adults

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection

A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers

Improving Sleep Quality After Total Joint Arthroplasty ( TJA)

Essential Oil Inhalation and Acute Stress Response in Healthy Adults

Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1

Nurse Managed Upper Body Strength Training in Chronic Obstructive Pulmonary Disease (COPD)

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy

A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors

Platelet Rich Plasma Uterine Infusion

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

Reactive Balance Training for Fall Prevention